MedTrace Logo

Jejunoileal vs Gastric GIST in the Era of Imatinib.

NCT03923400 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77

Last updated 2019-04-22

No results posted yet for this study

Summary

Introduction: Gastrointestinal Stromal Tumors (GISTs) located in the jejunum or ileum (JI-GIST) are considered of worse prognosis compared to other locations. It has been suggested that this dogma should be revised. The aim of this study is to describe the characteristics of jejunoileal GISTs and its prognosis; and to compare them with gastric GISTs in the era of imatinib.

Patients and methods: We retrospectively reviewed the clinical histories of all the patients diagnosed with GISTs between January 2000 and November 2016. Clinical and pathological data, as well recurrence, metastatic, disease-free survival (DFS) as overall (OS) rates of patients with JI-GIST or gastric GIST (G-GIST) were collected and compared.

Conditions

  • Disease-free Survival
  • Overall Survival
  • Recurrence

Sponsors & Collaborators

  • Hospital Universitario Virgen de la Arrixaca

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-01
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03923400 on ClinicalTrials.gov